Autologous serum (AS; 20-50%) has been used as a tear substitute for severe dry eye patients. Protocols for preparation of AS are available 1-3 but there is no universally accepted methodology, which hinders regulatory approval and widespread clinical use. Here, we report an approach that utilizes 100% autologous plasma (AP) directly from plasmapheresis, which minimizes contamination. In this 'closed' system, plasma collected is directly portioned into single-use segments within tubings.
Case report
The study was approved by the Singhealth Institutional Review Board and adhered to the tenets of the Declaration of Helsinki. After informed written consent, 10 patients with recalcitrant dry eye (6 women and 4 men, mean ± SD age: 57.4 ± 10.5 years) and tested negative for hepatitis B, HIV, and syphilis underwent plasmapheresis. A plasma volume of 110 ml was collected in a closed bag over a 30-min period. Plasma was dispensed into intravenous tubings and crimped into 1-2-inch segments with the Genosys multi-head crimper. Patients stored the plasma in their freezers and defrosted the required segments in the fridge at 4 1C daily. Eyedrops were used 3-4 times/day in addition to current medication over a 6-week period.
We identified significantly reduced fluorescein staining scores in most zones of the cornea after treatment (Po0.01, Table 1 ). Severity and frequency of dry eye symptoms improved in 50% of the patients as assessed by visual analog scale, while no change or worsening of symptoms was experienced by 30 and 20% of patients, respectively. The overall change in dry eye symptoms in the group was not statistically significant ( 
Comment
The AP treatment dispensed in single-use segments, which minimizes microbial contamination, has the potential to be used more widely for recalcitrant dry eye. 4, 5 Cost-effectiveness studies are necessary in different healthcare environments.
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